Botanical species · safety record

Dysphania ambrosioides

The EFSA Compendium of Botanicals holds 12 constituent measurements, 2 adverse-effect records and 1 genotoxicity assay for Dysphania ambrosioides. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Dysphania ambrosioides (L.) Mosyakin & Clemants

12Constituent measurements

3Safety records

8Cited sources

3Licensed products (Canada)

Also recorded as

Chenopodium ambrosioides L.
Dysphania anthelmintica (L.) Mosyakin & Clemants

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 3 licensed products naming Dysphania ambrosioides as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Source material stated

Seed(s)

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Alkaloids	Unspecified	Solvent extraction	—	Phytochemical screening	Resolve DOI
Ascaridol	Aerial part of plants	Essential oil	92.04 Percent	—	Resolve DOI
Ascaridol	Unspecified	Essential oil	≤ 1.8 Percent	GC-MS	Resolve DOI
Ascaridol	Live plants	Essential oil	43.4 Percent	GC-MS	Resolve DOI
Ascaridol	Leaves	Essential oil	49.77 Percent	GC-MS	Resolve DOI
Ascaridol	Live plants	Essential oil	6.38 Percent	GC-MS	Resolve DOI
Camphor	Live plants	Essential oil	12.4 Percent	GC-MS	Resolve DOI
Cardiac glycosides	Unspecified	Solvent extraction	—	Phytochemical screening	Resolve DOI
Phlobotannins	Unspecified	Solvent extraction	—	Phytochemical screening	Resolve DOI
Pinocarvone	Live plants	Essential oil	4.63 Percent	GC-MS	Resolve DOI
Saponins	Unspecified	Solvent extraction	—	Phytochemical screening	Resolve DOI
Tannins	Unspecified	Solvent extraction	—	Phytochemical screening	Resolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Hepatotoxicity	Liver	Leaves	Solvent extraction	Rat (as animal)	Short-term toxicity	Resolve DOI
Hepatotoxicity	Liver	Leaves	Solvent extraction	—	Case report	Resolve DOI

Genotoxicity testing

Outcomes of genotoxicity assays as recorded in the source. A negative assay is a result under those test conditions, not a clearance.

Outcome	Endpoint	Test	Tested organism	Metabolic activation	Source
Positive	chromosome aberration	sister chromatid exchange assay in mammalian cells	Human (as organism)	No data	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Khan, Amir Muhammad., Qureshi, Rizwana Aleem., Ullah, Faizan., Gilani, Syed Aneel., Nosheen, Asia., Sahreen, Sumaira., Laghari, Muhammad Khan., Laghari, Muhammad Yousif., Shafiq-Ur-Rehman., Hussain, Ishtiaq., Murad, Waheed. Phytochemical analysis of selected medicinal plants of Margalla Hills and surroundings. JOURNAL OF MEDICINAL PLANTS RESEARCH, 2011, vol. 5, no. 25, p. 6017-6023. DOI
Pereira Paes, Joao Paulo., Rondelli, Vando Miossi., Costa, Adilson Vidal., Vianna, Ulysses Rodrigues., De Queiroz, Vagner Tebaldi. CHEMICAL CHARACTERIZATION AND EFFECT OF ESSENTIAL OIL FROM MEXICAN-TEA ON TWOSPOTTED SPIDER MITE . Revista brasileira de fruticultura, 2015, vol. 37, no. 2, p. 346-354. DOI
Blanckaert, Isabelle., Paredes-Flores, Martin., Espinosa-Garcia, Francisco J., Pinero, Daniel., Lira, Rafael. Ethnobotanical, morphological, phytochemical and molecular evidence for the incipient domestication of Epazote (Chenopodium ambrosioides L.: Chenopodiaceae) in a semi-arid region of Mexico . Genetic resources and crop evolution, 2012, vol. 59, no. 4, p. 557-573. DOI
Omidbaigi, R., Sefidkon, F., Nasrabadi, F.B. Essential oil content and compositions of chenopodium ambrosioides l. Journal of essential oil-bearing plants, 2005, vol. 8, no. 2, p. 154-158. DOI
da Silva, Marcel Gianni C., Amorim, Raimundo Neilson L., Camara, Carlos C., Fontenele Neto, Jose Domingues., Soto-Blanco, Benito. Acute and Sub-Chronic Toxicity of Aqueous Extracts of Chenopodium ambrosioides Leaves in Rats . Journal of medicinal food, 2014, vol. 17, no. 9, p. 979-984. DOI
Gadano, AB., Gurni, AA., Carballo, MA. Argentine folk medicine: Genotoxic effects of Chenopodiaceae family. Journal of ethnopharmacology, 2006, vol. 103, no. 2, p. 246-251. DOI
Degenhardt, Ruth T., Farias, Ingrid V., Grassi, Liliane T., Franchi, Gilberto C., Jr., Nowill, Alexandre E., Bittencourt, Christiane M. da S., Wagner, Theodoro M., de Souza, Marcia M., Cruz, Alexandre Bella., Malheiros, Angela. Characterization and evaluation of the cytotoxic potential of the essential oil of Chenopodium ambrosioides . Revista brasileira de farmacognosia-brazilian journal of pharmacognosy, 2016, vol. 26, no. 1, p. 56-61. DOI
Derraji, S., Mahassin, F., Rhalem, N., Ouzzif, Z. Hepatotoxicity by Chenopodium ambrosioides about 3 comments (collected in the Hospital Military Instruction Mohammed V, Rabat - Morocco) H�patotoxicit� par Chenopodium ambrosioides � propos de 3 observations (collig�es � l'h�pital militaire d'instruction Mohammed V, Rabat - Maroc) . Toxicologie analytique et clinique, 2014, vol. 26, no. 3, p. 176-180. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature